Colchicine is a treatment for gout that has been used for more than a millennium. It is the treatment of choice for familial Mediterranean fever and its associated complication, amyloidosis. The 2009 U.S. Food and Drug Administration approval of colchicine as a new drug had research consequences. Recent investigations with large cohorts of patients with gout who have been taking colchicine for years have demonstrated novel applications within oncology, immunology, cardiology and dermatology. Some emerging dermatological uses include the treatment of epidermolysis bullosa acquisita, leucocytoclastic vasculitis, aphthous stomatitis and others. In this work we relate the history and the new horizon of this ancient medicine.
History
Colchicine is one of the oldest remedies still in use today. It is derived from the bulb-like corms of the Colchicum autumnale plant, also known as autumn crocus. Its history as a herbal remedy for joint pain goes back at least to the 1500 BCE Egyptian manuscript, the Ebers Papyrus (Fig. 1) . The active ingredient, colchicine (Fig. 2) , was isolated in the early 1800s and remains in use today as a purified natural product. 1 In view of the long history of colchicine's use in medicine, it is perhaps surprising that it was not until 2009 that colchicine was approved by the U.S. Food and Drug Administration. 2 
Mechanism of action
Despite its use for thousands of years, colchicine's exact mechanism of action is still being explored. In the 1950s and 1960s the microtubule was identified as the primary cellular target. Microtubules serve as a major part of our cellular cytoskeleton, and are essential to cellular functions such as mitosis, as well as intracellular organelle and vesicle trafficking. 3, 4 Microtubule dynamics originate in a balance of polymer growth and shrinkage, mostly at the microtubule end that is distal to the nucleus. These dynamics allow changes in microtubule distribution and in overall cell shape (Fig. 3) . Structurally, microtubules are hollow cylinders composed of protofilaments, which in turn are made from ab-tubulin heterodimers polymerized end to end. Colchicine binds to tubulin heterodimers and alters the tubulin conformation, allowing the tubulin dimer-colchicine complex to add to the growing end of a microtubule but preventing any further growth, thus poisoning the dynamics of that microtubule. The exact mechanism by which this colchicine-induced microtubule destabilization leads to alteration of cell function remains unclear.
Colchicine impairs neutrophil function by having an impact on inflammatory pathways and mediators of neutrophil activation. The drug decreases neutrophil L-selectin expression and modulates E-selectin expression on the cell surface of endothelial cells, thereby impairing neutrophil recruitment. 5 It further prevents neutrophil migration by decreasing the inducing effects of platelet activating factor and leukotriene-b4 on neutrophil adherence. 6 Neutrophil function is additionally compromised by colchicine via suppression of neutrophil superoxide production, a key contributor to the inflammatory response seen in neutrophil activation. 7 By impairing vesicular trafficking, colchicine is able both to decrease tumour necrosis factor-a receptor expression on macrophages (preventing activation) and interrupt granule release in mast cells (preventing degranulation). 4 In keeping with this effect on inflammatory modulators, in vivo and in vitro studies demonstrate decreased levels of the proinflammatory cytokines interleukin (IL)-1b, interferon-c, IL-18 and IL-6 with colchicine use. 8 Given these extensive effects on inflammation, it is not surprising that the use of colchicine has been explored in a number of inflammatory conditions.
Traditional indications: the old Gout and pseudogout
Colchicine has been known as a treatment for gout for several millennia. Inflammation in gout is mediated by a combination of neutrophil and macrophage activation, leucocyte adhesion molecules, inflammasome activation as well as IL-1b production. As noted above, all of these pathways are affected by colchicine. 2 Despite its longstanding use, few randomized controlled trials (RCTs) have evaluated its efficacy empirically. In the first randomized, placebo-controlled trial assessing the efficacy and toxicity of colchicine in acute gout, patients were treated with an initial 1-mg dose followed by sequential doses of 0Á5 mg every 2 h until either significant symptomatic relief or intolerance. The authors found that two-thirds of patients treated with colchicine experienced pain reduction within 48 h whereas only one-third of patients in the placebo group Microtubules (red) were imaged by immunostaining with monoclonal anti-alpha tubulin antibody and the DNA in the nucleus (blue) was revealed by Hoechst stain. experienced a similar response; however, patients reported diarrhoea prior to relief of symptoms. 9 The AGREE (Acute Gout Flare Receiving Colchicine Evaluation) trial was the first randomized, placebo-controlled trial to compare low-and high-dose colchicine. In this study, 184 patients experiencing acute gout flares were randomized to either a low-dose regimen (1Á2-mg dose followed by one 0Á6-mg dose 1 h later), a high-dose regimen (1Á2-mg dose followed by one 0Á6-mg dose every hour up to a maximum of 4Á8 mg) or placebo. The authors found comparable response rates in the low-and the high-dose groups, with both superior to placebo. Importantly, they also noted that the high dose was associated with more diarrhoea and vomiting. 10 In addition to the use of colchicine in acute flares, evidence supports its use as a prophylactic agent in certain patients with chronic gout. A placebo-controlled randomized trial evaluating colchicine for flare prophylaxis in patients initiating allopurinol found that patients treated with colchicine had fewer and less severe flares. 11 An analysis of three RCTs evaluating 4101 patients initiating urate-lowering therapy with either febuxostat or allopurinol found that prophylactic colchicine taken for up to 6 months provided greater reduction in flare rates as compared with an 8-week course.
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Colchicine is also recommended for the treatment of acute flares, as well as flare prophylaxis, in patients with pseudogout or calcium pyrophosphate crystal arthritis. According to current European League Against Rheumatism guidelines, 0Á5 mg of colchicine should be prescribed for pseudogout prophylaxis, and 0Á5 mg three times daily, with or without a 1-mg loading dose, should be administered for acute attacks. 13 
Familial Mediterranean fever
Familial Mediterranean fever (FMF) is characterized by recurrent attacks of fever, arthritis and serositis. This condition is caused by a mutation in the gene that encodes pyrin, a protein that regulates inflammasome activation. This mutation permits exuberant IL-1b production and inflammatory attacks. 2 Colchicine has been the treatment of choice for FMF since the 1970s. Two seminal RCTs in 1974 found that patients treated with colchicine for 1-2 months experienced significantly fewer attacks.
14 Several long-term follow-up studies, including one longitudinal study in which 45 affected patients who have taken colchicine for a minimum of 15 years, provided favourable support for the safety and efficacy of this therapy. 15 Amyloid A amyloidosis, which occurs in up to 90% of people with untreated FMF, leads to chronic renal failure, typically within 5 years after the onset of proteinuria. Colchicine is considered to be the prophylactic treatment of choice for secondary amyloidosis. 16 Colchicine, in daily doses of 1-2 mg, not only prevents or significantly reduces the frequency of FMF attacks in 90-95% of patients, but it almost universally prevents the development of amyloidosis. 2 It has been shown to prevent development of proteinuria, which is the underlying aetiology of renal failure as a result of amyloidosis in patients with FMF. 17 Even in patients with established amyloid nephropathy, colchicine has been shown to induce remission of proteinuria and nephrotic syndrome. Additionally, a randomized cohort study showed favourable efficacy of colchicine in treatment of secondary amyloidosis. The same trial showed increased survival in a patient who received colchicine compared with the cohort who received a combination of melphalan and prednisone. 18 It is important to emphasize that use of colchicine is proven safe in children, as well as in pregnant and nursing women. 19 
Potential indications: the new
The potential uses of colchicine have broadened significantly over the past few years as new studies have emerged demonstrating novel applications within oncology, immunology, cardiology and dermatology. Many of these studies have used the large cohort of patients with gout who have been taking colchicine for years to decades in order to assess significant trends and associations.
Uses in dermatology
Colchicine has been reported to be an efficacious and well-tolerated treatment for numerous dermatological diseases; however, the data are mostly limited to small case reports and series. Behc ßet disease, epidermolysis bullosa acquisita, leucocytoclastic vasculitis, Sweet syndrome and recurrent aphthous stomatitis are some of the few dermatological diseases in which treatment with colchicine has been studied more extensively (Table 1) .
Behc ßet syndrome
Behc ßet syndrome is a systemic vasculitis characterized clinically by recurrent oral and genital ulceration, arthritis and uveitis, as well as variable cutaneous, gastrointestinal and neurological involvement. Studies have supported the efficacy of colchicine in the treatment of the mucosal, cutaneous, pleuropericardial and abdominal complications of this disease. Colchicine is hypothesized to exert its effect in Behc ßet syndrome through leucocyte chemotaxis. In 1975, Matsumara and Mizushima published details of the first study showing improvement in the condition with colchicine therapy; specifically, seven of 12 patients had moderate improvement in symptoms following treatment with colchicine 0Á5 mg twice a day. 20 Decades later, a double-blind controlled trial in which 116 patients with Behc ßet syndrome were randomized to receive either colchicine or placebo for 2 years showed significant reductions in the occurrence of genital ulcers, erythema nodosum and arthritis in female patients, as well as a reduction in the incidence of arthritic symptoms in men. 3, 21 Davitchi et al.
performed a crossover trial of 169 patients who fulfilled criteria for Behc ßet syndrome, in which patients were randomly assigned to receive colchicine or placebo for 4 months, and then swapped over (colchicine to placebo, placebo to colchicine) for an additional 4 months. The authors of this study found significant improvements in a validated outcome measure, the Iranian Behc ßet's Disease Dynamic Activity Measure, as opposed to worsening of the score in the placebo group. They also noted significantly reduced reports of oral and genital ulcers, pseudofolliculitis and erythema nodosum in the colchicine group. In contrast to the previous study, this study did not find a difference between results for male and female patients. 22 
Epidermolysis bullosa acquisita
Epidermolysis bullosa acquisita is a rare, mucocutaneous blistering disease with onset in adults that is characterized by autoantibodies against collagen VII. Subepidermal blisters occur after mild trauma and heal with significant scarring. The efficacy of colchicine in treating this disease was first reported in 1989. In a retrospective study of 30 patients with epidermolysis bullosa acquisita, colchicine was considered first-line therapy because of its low side-effect profile; a dose of 1Á2 mg per day was used. Patients additionally received dapsone and oral prednisone, and on this regimen, mean time to remission was 9 months. 23 Since then, there have been several case reports describing efficacy of monotherapy with colchicine for epidermolysis bullosa acquisita. The suggested mechanism of action of colchicine in this disease is through inhibition of antibody secretion. 24 In support of this theory, serum anti-type VII collagen antibody level titre decreased with colchicine treatment. Clinically, there was improvement in mucosal erosions, oesophageal stenosis, dysphagia symptoms and cutaneous erosions. Incidentally, the haemoglobin A1c of one patient with diabetes mellitus type 2 was found to improve on colchicine therapy without change in diabetic management. 24 
Leucocytoclastic vasculitis
Leucocytoclastic vasculitis is a common small vessel vasculitis that is characterized by palpable purpura and petechiae. Its aetiology is diverse with both primary causes such as Henoch-Sch€ onlein purpura and urticarial vasculitis, as well as secondary causes such as drugs, infections and malignancies. Despite efficacy for colchicine reported in multiple case reports, a prospective RCT of 41 patients showed no significant effect with colchicine 0Á5 mg daily vs. topical emollients alone. Importantly, three patients in the trial did have complete response and had recurrence of disease after cessation of colchicine. 25 
Sweet syndrome
Sweet syndrome (also known as acute febrile neutrophilic dermatosis) is a neutrophilic dermatosis first described in 1964 by Robert Douglas Sweet and characterized by an acute febrile illness with development of multiple tender, erythematous and oedematous plaques. The aetiology is not clear, but it is thought to be the result of a hypersensitivity reaction to an underlying disease. In a retrospective study of 90 patients, colchicine was the predominant treatment with 49% of the 27 Epidermolysis bullosa acquisita Retrospective trial or larger case series (> 20 patients)/small series or individual report 23, 24, 41 Granuloma annulare Small series or individual report 42 Henoch-Sch€ onlein purpura Small series or individual report 43 Hidradenitis suppurativa Small series or individual report 44, b Idiopathic plantar eccrine hidradenitis Small series or individual report 45 Linear IgA Small series or individual report 46, 47 Leucocytoclastic vasculitis Prospective controlled trial 25, b Neutrophilic urticaria Small series or individual report 48 Nodular vasculitis Small series or individual report 49 Purpura annularis telangiectoides Small series or individual report 50 Pyoderma gangrenosum Small series or individual report 51, 52 Recurrent aphthous stomatitis Prospective controlled trial/retrospective trial or larger case series (> 20 patients) 28, 29 Relapsing polychondritis Small series or individual report 53, 54 Scleredema Small series or individual report 55 Scleredema diabeticorum Small series or individual report 56 Sweet syndrome Retrospective trial or larger case series (> 20 patients) 26 Urticarial vasculitis Small series or individual report 57 a Topical colchicine was used; b no significant effect observed or not efficacious.
cohort receiving it. A dose of 1-2 mg per day was used with regression of lesions in 1-14 days in 30 patients (68%) receiving the drug. Of the 13 patients who did not respond to colchicine initially, there was improvement following the addition of prednisone. 26 
Chronic urticaria
Chronic urticaria is defined as urticarial lesions occurring at least twice a week without treatment for 6 weeks or more. A retrospective trial of 36 patients with chronic urticaria treated with colchicine for a mean duration of 7 months found that 56% of patients had a partial to complete response. Of the 15 patients with complete response, nine patients remained in remission. 27 
Recurrent aphthous stomatitis
Recurrent aphthous stomatitis presents as painful ulcerative or erosive lesions of the oral mucosa, and it may be idiopathic or secondary to an underlying immune disorder such as Behc ßet disease. Fontes et al. performed a retrospective trial of 54 immunocompetent patients with severe aphthous stomatitis, including those with Behc ßet disease and those with idiopathic disease. Patients were treated with colchicine 1-1Á5 mg per day for a minimum of 3 months. After 3 months, 12 patients were disease free, 22 patients had at least 50% decrease in frequency and duration of lesions and 20 patients had no improvement or did not tolerate treatment. At follow-up of 72 months, four patients had no recurrence of disease. 28 Similar findings were reported in a double-blind randomized trial of 34 patients randomized to 0Á5 mg daily of colchicine vs. 5 mg daily of prednisolone for recurrent aphthous stomatitis. Patients were treated for 3 months and both treatment groups had significant improvement in duration, symptoms, recurrence of lesions and size of lesions. No significance difference in efficacy was found between either treatment group; however, patients treated with colchicine did report more adverse events, primarily gastrointestinal symptoms. 29 
Actinic keratosis
Actinic keratoses are common premalignant lesions with an approximately 10% risk of transforming into cutaneous squamous cell carcinoma over 10 years if left untreated. Recently, a double-blind randomized trial was performed of 70 actinic keratoses treated with 1% topical colchicine gel vs. 3% diclofenac gel twice a day for 3 weeks. In both treatment groups, there was a significant reduction in size of lesions after treatment. There was no difference in size of lesions at 30, 60 and 120 days after treatment. Notably, colchicine gel was better tolerated than diclofenac gel, as over 20% of patients in the latter group reported erythema vs. no patients in the colchicine group. 30 A randomized trial of 16 patients with actinic keratoses treated with 0Á5% vs. 1% colchicine cream twice a day for 10 days found both concentrations to be efficacious in reduction in size and number of actinic keratoses, with resolution in six of eight patients treated with 1% colchicine and seven of eight patients treated with 0Á5% colchicine. No significant difference in efficacy was found between concentrations. 31 A randomized double-blind trial of 20 patients treated with 1% colchicine gel vs. placebo reported similar results with resolution of actinic keratoses in seven of 10 patients treated with 1% colchicine gel. Burning and itching at day 2 or 3 of application was the only reported adverse effect with treatment.
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Uses in other, nonrheumatological or dermatological diseases
One study published in 2015 sought to explore the relationship between colchicine use and the incidence of cancer. This study examined rates of malignancy in 24 000 male patients with gout in Taiwan, comparing cancer incidence in 'everusers' and 'never-users' of colchicine. The results demonstrated significantly lower incidence of all-cause cancers after adjustment for age in the colchicine ever-users when compared with the never-users; findings were especially significant for prostate and colorectal cancers. 33 According to ongoing oncological investigations, colchicine appears to be one of the promising candidates on the horizon for combination chemoprevention agents or hybrid chemotherapy. 34 Recent cohort studies have also examined the effects of colchicine on myocardial infarction and other cardiovascular events. Crittenden et al. first assessed the relationship between myocardial infarction and colchicine in patients with gout, finding a significantly decreased prevalence of myocardial infarction in the colchicine-treated group than in the noncolchicine group (1Á2% vs. 2Á6%), with a trend towards decreased all-cause mortality. 35 A more recent study assessing the rate of cardiovascular events in patients with gout found colchicine users to have a 49% lower risk of primary cardiovascular events than noncolchicine users and a 73% reduction in all-cause mortality. 36, 37 Numerous controlled clinical trials support the safety and efficacy of a daily dose of colchicine for the treatment and prevention of acute pericarditis from multiple causes. The 2004 European Society of Cardiology recommended colchicine for this purpose, based on small, nonrandomized trials. 2 Since then, multiple RCTs have supported this recommendation, including the CORE trial (COLchicine for REcurrent pericarditis), which found a 51% reduction in the rate of recurrent pericarditis in patients treated with colchicine for 18 months compared with 24% in the placebo group (P = 0Á02) as well as the Colchicine for Recurrent Pericarditis (CORP) study and the recently published CORP-2 trial, which reported a significant reduction in the rate of subsequent recurrences of pericarditis in patients with two or more recurrences.
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Conclusions
The list of therapeutic and prophylactic applications for colchicine in multiple fields of medicine is lengthening as our appreciation of the anti-inflammatory properties of this natural drug expand and as our understanding of the many mechanisms affected by colchicine's action deepens (Fig. 4) . A number of dermatological diseases have already been found to respond to colchicine, and more thorough studies will likely reveal new uses for this ancient drug.
